ATE526969T1 - Behandlung von depressionen und depressiven stimmungen - Google Patents

Behandlung von depressionen und depressiven stimmungen

Info

Publication number: ATE526969T1
Authority: AT; Austria
Prior art keywords: reserpine; administered; compound; depression; treatment
Prior art date: 2007-07-17

Application number

AT07252828T

Other languages

English (en)

Inventor

Elaine A Delack

Original Assignee

Meddev Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-17

Filing date

2007-07-17

Publication date

2011-10-15

2007-07-17 Application filed by Meddev Inc filed Critical Meddev Inc

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526969T1 publication Critical patent/ATE526969T1/de

Links

208000020401 Depressive disease Diseases 0.000 title abstract 2
230000003001 depressive effect Effects 0.000 title abstract 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 abstract 4
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 abstract 4
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 abstract 4
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 abstract 4
229960003147 reserpine Drugs 0.000 abstract 4
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 abstract 4
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 2
229960001948 caffeine Drugs 0.000 abstract 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 2
-1 caffeine compound Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
OBFAPCIUSYHFIE-UHFFFAOYSA-N (5-hydroxyindol-3-yl)acetaldehyde Chemical compound OC1=CC=C2NC=C(CC=O)C2=C1 OBFAPCIUSYHFIE-UHFFFAOYSA-N 0.000 abstract 1
102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
108010062431 Monoamine oxidase Proteins 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
230000003197 catalytic effect Effects 0.000 abstract 1
239000006071 cream Substances 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
230000000946 synaptic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Botany (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

AT07252828T 2007-07-17 2007-07-17 Behandlung von depressionen und depressiven stimmungen ATE526969T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07252828A EP2022499B1 (de)	2007-07-17	2007-07-17	Behandlung von Depressionen und depressiven Stimmungen

Publications (1)

Publication Number	Publication Date
ATE526969T1 true ATE526969T1 (de)	2011-10-15

Family

ID=38760198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07252828T ATE526969T1 (de)	2007-07-17	2007-07-17	Behandlung von depressionen und depressiven stimmungen

Country Status (2)

Country	Link
EP (1)	EP2022499B1 (de)
AT (1)	ATE526969T1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7232830B2 (en) *	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
US6559293B1 (en) *	2002-02-15	2003-05-06	Transform Pharmaceuticals, Inc.	Topiramate sodium trihydrate

2007
- 2007-07-17 AT AT07252828T patent/ATE526969T1/de not_active IP Right Cessation
- 2007-07-17 EP EP07252828A patent/EP2022499B1/de not_active Not-in-force

Also Published As

Publication number	Publication date
EP2022499B1 (de)	2011-10-05
EP2022499A1 (de)	2009-02-11

Similar Documents

Publication	Publication Date	Title
Candow et al.	2023	“Heads up” for creatine supplementation and its potential applications for brain health and function
Weng et al.	2016	Apigenin reverses depression-like behavior induced by chronic corticosterone treatment in mice
Ravindran et al.	2009	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.: V. Complementary and alternative medicine treatments
EA201490279A1 (ru)	2014-08-29	Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112012018500A2 (pt)	2016-08-16	alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EA200971053A1 (ru)	2010-06-30	Способы лечения кожных язв
MX2009013989A (es)	2010-03-09	Terapia en combinacion para depresion.
CO6251212A2 (es)	2011-02-21	Tratamiento terapeutico de sindrome metabolico diabetes tipo 2 obesidad o prediabetes
WO2009073544A3 (en)	2009-08-27	Methods for treating a disorder by regulating gprc6a
EA201790406A1 (ru)	2017-11-30	Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201200975A1 (ru)	2012-12-28	Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
CO6640335A2 (es)	2013-03-22	Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CO6771410A2 (es)	2013-10-15	Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad o prediabetes
Jones et al.	2013	A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats
EA200600921A1 (ru)	2006-10-27	Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
MX2013008715A (es)	2013-08-29	Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
Ren et al.	2018	Anesthetics alleviate learning and memory impairment induced by electroconvulsive shock by regulation of NMDA receptor-mediated metaplasticity in depressive rats
UA112418C2 (uk)	2016-09-12	Терапевтичний болезаспокійливий засіб
MX2009009171A (es)	2010-03-04	Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.
BRPI0514397A (pt)	2008-06-10	derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon
JP2014513130A5 (de)	2015-04-23
DE602007014193D1 (de)	2011-06-09	Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
ATE526969T1 (de)	2011-10-15	Behandlung von depressionen und depressiven stimmungen
Amancio-dos-Santos et al.	2013	Tianeptine facilitates spreading depression in well-nourished and early-malnourished adult rats
MY170152A (en)	2019-07-09	Ethynyl derivative as modulators of mglur5 receptor activity

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties